HK inno.N to develop COVID-19 vaccine
Jun. 10, 2020
HK inno.N to develop COVID-19 vaccine
- Started developing COVID -19 vaccine candidates with CEVI (Novel Virus) Convergence Research Group
HK inno.N (formerly CJ Healthcare), a subsidiary of Kolmar Korea, starts developing the COVID - 19 vaccine.
HK inno.N signed a technology transfer agreement with the 'CEVI (New Virus) Convergence Research Group Technology Transfer Agreement' on COVID-19 (Corona 19) vaccine candidate held at the Korea Research Institute of Chemical Technology (located in Yuseong-gu, Daejeon) on the 9 and has entered into a joint study.
The 'high-efficiency coronavirus infection-19 (SARS-CoV-2;Corona19) vaccine candidate' previously received by HK inno.N was developed by the CEVI Convergence Research Group of the National Research Council of Science and Technology under the Ministry of Science and ICT.
The candidate is used in the development of vaccine drugs to prevent Covid-19 and mutant Covid-19 infections in humans. HK inno.N and CEVI Convergence Research Group will conduct joint research for preclinical and clinical trials. It will also conduct joint research to develop a new pneumococcal vaccine in the future.
The new vaccine candidate previously received by HK inno.N is a synthetic antigen vaccine and it was found to have 3 to 5 times higher neutralizing antibody capacity than other candidates currently in development. The 'neutralizing antibody capacity', which indicates the efficacy of the vaccine, is the ability to generate antibodies that bind to the antigen in the human body and neutralize the activity of the antigen when the vaccine antigen is administered to the body. The high neutralizing antibody capacity means that it is possible to prevent Covid-19 in both mild and severe patients.
HK inno.N has developed and has exported new and biopharmaceuticals and has been recognized for its research capabilities in pharmaceutical biotechnology. HK inno.N succeeded in developing K-CAB Tab. (a treatment for GERD), Korea's 30th new drug, and advanced into 23 countries including Korea. In the field of biopharmaceuticals, it succeeded in developing EPO (treatment for renal anemia) formulation the third in the world and the first in Korea. The second generation EPO, which has improved the number of doses compared to the first generation products, has exported technology to China and Japan, and is also researching bivalent hand, foot and mouth disease (1st phase approval), smallpox and pneumococcal vaccines. HK inno.N plans to concentrate its accumulated biopharmaceutical development capabilities on the development of this Covid-19 vaccine.